COMMUNIQUÉS West-GlobeNewswire

Baba Appoints Former Mount Sinai Executive Director to Lead Clinical Operations
20/04/2026
Platform taps decade+ of health system clinical leadership to scale virtual, longitudinal advocacy for Medicare, Medicare Advantage, and Medicaid populations NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Baba, an [...]
Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA
20/04/2026
ORION CORPORATION PRESS RELEASE 20 APRIL 2026 at 16.00 EEST Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA Orion Corporation (Orion Pharma) today announced that its investigational [...]
Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026
20/04/2026
Updated AACR poster data show continued survival follow-up in heavily pre ‑ treated patients following a single intratumoral UNO injection Received US patent allowance covering proprietary gas delivery technology for [...]
Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions
20/04/2026
NEW YORK and TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“ [...]
Nanox Signs Commercial Agreement with Howard Technology Solutions to Deploy 300 Nanox.ARC Systems Across U.S. Over Three Years
20/04/2026
Howard’s nationwide reach across healthcare and public sector markets expands Nanox’s U.S. channel partner network to additional customer segments PETAH TIKVA, Israel, April 20, 2026 -- Nano-X Imaging Ltd. (“Nanox”, or [...]
Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing
20/04/2026
Superior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor models Novel RNA spliceosome-targeting payload PH1 shows potential to overcome Topoisomerase I inhibitor resistance [...]
Atsena Therapeutics Receives Data Monitoring Committee Recommendation to Proceed with Pivotal Part C Cohort of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
20/04/2026
Patient screening to begin this month DURHAM, N.C., April 20, 2026 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse [...]
Omega Laboratories to Host Educational Panels and Present Cannabix Marijuana Breath Test Solution at the 2026 NDASA Conference in California
20/04/2026
VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) a developer of marijuana and alcohol breath-testing [...]
BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure
20/04/2026
SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today [...]
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
20/04/2026
WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical [...]
Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV108, an Allosteric SARM1 inhibitor
20/04/2026
Second candidate from Tenvie’s product engine to enter clinical development Phase 1 first-in-human study to evaluate single and multiple ascending doses of TNV108 in healthy volunteers Preliminary data expected in the [...]
AskBio's Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Disease
20/04/2026
Berlin, Germany, and Durham, N.C., USA, April 20, 2026 (GLOBE NEWSWIRE) -- Not intended for UK Media Ametefgene parvec (AB-1005) manufactured at Viralgen commercial manufacturing facility with next-generation process to [...]
LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom
20/04/2026
MHRA submission follows EMA validation of the VIZZ MAA in March 2026 Sixth ex-U.S. regulatory submission for VIZZ underscores accelerating global expansion SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics [...]
Vystar Enters into Binding Letter of Intent to Acquire 50% Interest in R3alm Inc.
20/04/2026
A Compliance-Focused AI and Web3 Financial Ecosystem Proposed Transaction Includes Joint Development Framework, Vystar Series B Consideration, and Strategic Alignment Around the R3EQ Ecosystem ■ ■ ■ Vystar to Receive [...]
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
20/04/2026
DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in [...]
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
20/04/2026
AUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a sector [...]
Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
20/04/2026
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, presented [...]
ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy
20/04/2026
Inside Information The ALLIANCE phase 2 trial demonstrated proof-of-concept after only 6 months of maintenance treatment in a broad patient population comprising both children and adults. Clear dose-dependent and [...]
Scilex Holding Company Announces Its Board of Directors Approved a Dividend of Dream Bowl I Meme Coin Tokens to Holders of Common Stock and other Eligible Equity Securities with a Record Date of April 30, 2026
20/04/2026
PALO ALTO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non [...]

Pages